Most Read Articles
Pearl Toh, 2 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
6 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 07 Dec 2018
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.
Yesterday
Rates of major bleeding events are similar across cancer patients taking direct oral anticoagulants (DOAC), low-molecular-weight heparin (LMWH) or vitamin K antagonist (VKA), with gastrointestinal bleeding being the most frequent event, a recent study has shown. In addition, DOAC and LMWH recorded higher rates of venous thromboembolism than earlier studies.

Waist-to-hip ratio tied to MACE risk in females with coronary artery disease

14 Apr 2018

There appears to be a link between waist-to-hip ratio (WHR) and higher risks of major adverse cardiac events (MACEs) in females with coronary artery disease, according to a recent study.

Over a median follow-up of 5.7 years, 415 patients experienced at least 1 MACE event. Multivariate models showed that females in the highest WHR tertile had significantly higher risk of MACE relative to those in the lowest tertile (hazard ratio [HR], 1.85; 95 percent CI, 1.16–2.94; p=0.01).

Treating WHR as a continuous variable resulted in a similar trend. Each 0.10-unit rise in WHR was associated with a significant increase in the risk of MACEs in females (HR, 1.32; 1.08–1.61; p=0.007). All associations were robust to adjustments for body mass index (BMI)

In contrast, central obesity, as measured by WHR, did not seem to significantly affect MACE risk in males (HR for third vs first tertile, 0.92; 0.69–1.22; p=0.54; HR for each 0.10-unit increase in WHR, 0.98; 0.85-1.13; p=0.81).

The study included 1,529 CAD patients (mean age 63.1±12.5 years; 74 percent male) referred to cardiac rehabilitation. Participants were classified according to BMI groups and sex-specific tertiles of WHR. A composite outcome of stroke, death, ventricular arrhythmia, revascularization and acute coronary syndrome was used to define MACEs.

Clinically, “[a]n early assessment of central adiposity in addition to BMI and application of lifestyle changes focused on caloric balance, healthy nutrition and tailored exercise prescription may have a positive impact on [CAD] patients,” said researchers.
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 2 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
6 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 07 Dec 2018
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.
Yesterday
Rates of major bleeding events are similar across cancer patients taking direct oral anticoagulants (DOAC), low-molecular-weight heparin (LMWH) or vitamin K antagonist (VKA), with gastrointestinal bleeding being the most frequent event, a recent study has shown. In addition, DOAC and LMWH recorded higher rates of venous thromboembolism than earlier studies.